The study, published in October 2025, addresses a critical question in prostate cancer screening with Stockholm3: whether cancers detected at low PSA levels but with elevated Stockholm3 scores are clinically meaningful. This long-term follow-up from the population-based STHLM3 study shows that they are. Men diagnosed with prostate cancer at PSA levels below 3 ng/mL but with elevated Stockholm3 scores were approximately nine times more likely to experience high-risk biochemical recurrence after curative treatment compared to men who had higher PSA levels but low Stockholm3 risk (HR 8.8; 95% CI: 1.06–72).[1]

These findings demonstrate that Stockholm3 identifies biologically aggressive cancers that are often missed by traditional PSA-based screening. Without Stockholm3, many of these cancers would remain undetected at earlier stages and may progress beyond the window of curability.

European Urology selects a limited number of Editor’s Choice articles that the editors consider to be of particular importance in the field.

“This recognition from European Urology underscores the strength of the clinical evidence behind Stockholm3 and the importance of more precise prostate cancer screening strategies,” says Martin Steinberg, CEO of A3P Biomedical. “We are encouraged to see the study receiving this level of editorial attention from the leading journal in the field.”

[1] Vigneswaran, Hari T et al. “Stockholm3 Versus Prostate-specific Antigen in Prostate Cancer Screening: 9-year Outcomes Demonstrating Improved Detection of Aggressive Cancers and Reduced Overdiagnosis from the STHLM3 Trial.” European urology vol. 89,1 (2026): 82-90. doi:10.1016/j.eururo.2025.10.001